Protagonist Reports First Quarter 2022 Financial Results and

Initiated Phase 3 VERIFY study of rusfertide in polycythemia vera, reaffirming rusfertide in PV as the Company's primary point of focus Presented topline...

Related Keywords

United States , Russia , Ukraine , American , Pbruce Sands , Jami Taylor , Joshuar Mansbach , Ronald Hoffman , Kevin Murphy , Dineshv Patel , Exchange Commission , Center Study To Evaluate The Safety , Development Rd Expenses , Icahn School Of Medicine At Mount Sinai , Drug Administration , Protagonist Therapeutics Inc , Initiated Phase , Chief Executive Officer , Digestive Disease Week , Subcutaneous Injectable Hepcidin Mimetic , Polycythemia Vera , Annual Meeting , American Society , Clinical Oncology , Breakthrough Therapy Designation , Liver Meeting , American Association , Ulcerative Colitis , Multi Center Study , Peptide Antagonist , Severe Ulcerative Colitis , Icahn School , Cash Equivalents , Marketable Securities , Collaboration Revenue , Janssen Frontier , Private Securities Litigation Reform Act , Consolidated Statements , Months Ended ,